ENDPOINTS

Reproductive health biotech ReproNovo closes $65M Series A

A Swiss biotech has secured $65 million to launch a trio of mid-stage trials for two reproductive health drugs. ReproNovo announced the close of its Series A round on Wednesday. CEO Jean Marie Duvall co ...

May 21, 2025 - 09:24
 0
Reproductive health biotech ReproNovo closes $65M Series A
A Swiss biotech has secured $65 million to launch a trio of mid-stage trials for two reproductive health drugs. ReproNovo announced the close of its Series A round on Wednesday. CEO Jean Marie Duvall co ...
Read More

Tags:

Previous Article

Millet isotopes reveal advanced agriculture in early imperial China

Next Article

Altos Labs buys anti-aging startup Dorian Therapeutics

Related Posts

Enliven stops work on solid tumor drug; Pulmatrix to divest assets

Enliven stops work on solid tumor drug; Pulmatrix to di...

May 15, 2025  0

Galapagos backpedals on separation plans, CEO Paul Stoffels exits early

Galapagos backpedals on separation plans, CEO Paul Stof...

May 13, 2025  0

Arcturus to prioritize mRNA therapeutics in bid to boost rare disease programs

Arcturus to prioritize mRNA therapeutics in bid to boos...

May 13, 2025  0